AllenderSScharbotoughPPetoVRaynerMLealJLuengo-FernándezRGrayA. European cardiovascular disease statistics: 2008 editionLondon: British Heart Foundation; 2008.
2.
LealJLuengo-FernándezRGrayAPetersenSRaynerM. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J2006; 27:1610–1619.
3.
LopezAMathersCDEzzatiMJamisonDMurrayC. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet2006; 367:1747–1757.
4.
GrahamIAtarDBorch-JohnsenKBoysenGBurellGCifcovaREuropean Guidelines on Cardiovascular Disease Prevention in Clinical Practice: fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)Eur J Cardiovasc Prev Rehabil2007; 14 (Suppl 2): S1–S113. Executive summary: Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2):E1–E40; Eur Heart J 2007; 28:2375–2414.
5.
PyöräläKDe BackerGGrahamIPoole-WilsonPAWoodD. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerotic Society and European Society of Hypertension. Eur Heart J1994; 15:1300–1331.
6.
EUROASPIRE Study Group.EUROASPIRE. A European Society of Cardiology Survey of Secondary Prevention of Coronary Heart Disease: principal results. Eur Heart J1997; 18:1569–1582.
7.
ASPIRE Steering Group.A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart1996; 75:334–342.
8.
WoodDDe BackerGFaergemanDGrahamIManciaGPyöräläK. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J1998; 19:1434–1503.
9.
EUROASPIRE Study Group.Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programme. Eur Heart J2001; 22:554–572.
10.
EUROASPIRE Study Group.Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet2001; 357:995–1001.
11.
De BackerGAmbrosioniEBorch-JohnsenKBoysenGBurellGCifcovaREuropean guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)Eur J Cardiovasc Prev Rehabil2003; 10 (Suppl 1):S1–S78.
12.
KotsevaKWoodDDe BackerGDe BacquerDPyoralaKKeilU., on behalf of EUROASPIRE study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from twenty two European countries. EUROASPIRE Study GroupEur J Cardiovasc Prev Rehabil2009; 16:121–137.
13.
KotsevaKWoodDDe BackerGDe BacquerDPyoralaKKeilU., on behalf of EUROASPIRE study Group. Cardiovascular prevention guidelines-the clinical reality: a comparison of EUROASPIRE I, II and III surveys in 8 European countriesLancet2009; 372:929–940.
14.
KotsevaKWoodDDe BacquerDHeidrichJDe BackerG; on behalf of the EUROASPIRE II Study Group. Cardiac rehabilitation for coronary patients: lifestyle, risk factor and therapeutic management. Results from the EUROASPIRE II surveyEur Heart J2004; 6 (Suppl J):J17–J26.
15.
WoodDAKotsevaKJenningsCMeadAJonesJHoldenA; on behalf of the EUROACTION Study Group. EUROACTION: a European Society of Cardiology demonstration project in preventive cardiologyEur Heart J2004; 6 (Suppl J):J3–J15.
16.
WoodDAKotsevaKConnollySJenningsCMeadAJonesJ, on behalf of EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trialLancet2008; 371:1999–2012.